Cited 0 times in 
Cited 0 times in 
PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup
https://orcid.org/0000-0002-1595-6342Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.